Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
CAMBRIDGE, Mass. and SEOUL, South Korea, Jan. 8, 2024 /PRNewswire/ — Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.
Related news for (DNLI)
- Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
- Breaking News: MoBot’s Latest Update as of 04/02/25 02:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/02/25 01:00 PM
- 24/7 Market News Snapshot 02 April, 2025 – Denali Therapeutics Inc. Common Stock (NASDAQ:DNLI)
- Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program